1. Home
  2. KN vs ZYME Comparison

KN vs ZYME Comparison

Compare KN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Knowles Corporation

KN

Knowles Corporation

N/A

Current Price

$24.95

Market Cap

2.0B

ML Signal

N/A

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

N/A

Current Price

$23.23

Market Cap

1.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
KN
ZYME
Founded
1946
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Appliances
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.0B
1.8B
IPO Year
2013
2022

Fundamental Metrics

Financial Performance
Metric
KN
ZYME
Price
$24.95
$23.23
Analyst Decision
Buy
Strong Buy
Analyst Count
3
11
Target Price
$22.33
$38.90
AVG Volume (30 Days)
553.8K
625.3K
Earning Date
05-08-2026
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
118.94
33.33
EPS
0.50
N/A
Revenue
$593,200,000.00
$105,965,000.00
Revenue This Year
$9.40
$162.82
Revenue Next Year
$6.98
N/A
P/E Ratio
$50.84
N/A
Revenue Growth
7.17
38.87
52 Week Low
$12.19
$9.03
52 Week High
$28.74
$28.49

Technical Indicators

Market Signals
Indicator
KN
ZYME
Relative Strength Index (RSI) 42.02 46.30
Support Level $23.81 $22.23
Resistance Level $25.33 $23.66
Average True Range (ATR) 0.89 1.37
MACD -0.38 0.07
Stochastic Oscillator 23.93 17.07

Price Performance

Historical Comparison
KN
ZYME

About KN Knowles Corporation

Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: